Table 1

Baseline characteristics of participants in the AMIS Study (Number = 4,352)

Aspirin group

Placebo group


Quartile 1

Quartile 2

Quartile 3

Quartile 4

Total

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Total


sUA range, mg/dL men

2.5-4.5

4.52-5.37

5.38-6.45

6.47-10.45

2.50-10.45

2.38-4.48

4.5-5.42

5.47-6.48

6.52-11.05

2.38-11.05

women

1.4-5.25

5.27-6.03

6.05-7

7.02-12.52

1.40-12.52

1.83-5.28

5.3-6.03

6.05-6.97

6.98-12.12

1.83-12.12

Number

543

541

541

544

2,169

547

539

551

546

2,183

Mean sUA, mg/dL (SD)

4.55

(0.57)

5.55

(0.34)

6.44

(0.34)

8.05

(0.99)

6.15

(1.43)

4.59

(0.57)

5.61

(0.3)

6.43

(0.32)

7.93

(0.91)

6.14

(1.35)

Demographics

Age at first MI, years (SD)

52.6

(8.0)

52.5

(8.0)

52.6

(8.3)

52.8

(8.2)

52.6

(8.1)

53.0

(7.6)

52.7

(8.1)

52.5

(8.0)

52.7

(7.9)

52.7

(7.9)

Age at most recent MI, years (SD)

53.1

(7.8)

53.1

(7.9)

53.1

(8.3)

53.5

(8.0)

53.2

(8.0)

53.5

(7.6)

53.1

(8.0)

52.9

(7.9)

53.4

(7.8)

53.2

(7.8)

Age at randomization, years (SD)

54.8

(8.0)

54.8

(8.0)

54.8

(8.4)

55.1

(8.1)

54.9

(8.1)

55.2

(7.6)

54.8

(8.1)

54.5

(8.0)

55.0

(7.9)

54.9

(7.88)

Body mass index, kg/m2 (SD)

24.8

(3.2)

25.6

(3.3)

26.1

(3.2)

27.1

(3.7)

25.9

(3.5)

25.1

(3.1)

25.6

(3.2)

26.4

(3.4)

26.8

(3.8)

26.0

(3.5)

Men, %

88.8

88.2

88.4

88.6

88.5

89.8

89.4

89.7

89.7

89.6

African American, %

5.7

4.3

6.7

9

6.4

7.1

5.9

3.1

7.5

5.9

Physical examination data

Sedentary lifestyle, %

16.7

16.3

17.4

21.3

17.9

16.8

15.6

15.4

20.9

17.2

Alcohol usea, %

88.4

84.7

82.1

82

84.3

88.1

84.6

85.3

80.6

84.7

Smokerb, %

40.7

40.1

31.8

29.6

35.5

39.9

37.3

31.2

32.8

35.3

Heavy smokerc, %

10.1

10.3

12.1

10

10.6

7.2

5.8

15.7

11.4

9.8

Systolic blood pressure, mmHg (SD)

126.4

(15.6)

126.1

(15.4)

129.0

(16.6)

129.6

(16.5)

127.8

(16.1)

127.5 (17.1)

127.1

(15.1)

128.5

(15.5)

129.5

(16.9)

128.2 (16.2)

Diastolic blood pressure, mmHg (SD)

78.3

(9.4)

78.9

(8.9)

79.6

(9.2)

81.7

(9.8)

79.6

(9.4)

79.2

(9.3)

78.9

(8.9)

80.3

(9.4)

81.9

(10.0)

80.1

(9.5)

Laboratory data

Total glucose, mg/100 ml (SD)

148.8

(56.8)

155.4

(57.7)

158.4 (50.1)

171.2

(49.9)

158.6

(54.3)

159.1 (67.5)

156.7

(53.3)

160.1

(50.5)

168.9

(52.2)

161.2

(56.3)

Total cholesterol, mg/dL (SD)

230.4

(44.7)

235.7

(43.3)

240.4 (43.2)

243.2

(49.0)

237.7

(45.5)

234.0 (43.2)

235.1 (42.4)

240.2

(41.8)

241.2

(42.5)

237.7 (42.5)

Triglycerides, mg/dL (SD)

160.7 (130.0)

173.3

(101.6)

190.6 (149.1)

228.7 (192.2)

189.9 (159.2)

153.3

(86.2)

162.7 (97.0)

191.5 (116.6)

230.1 (169.3)

185.2 (125.7)

Comorbidities, %

Number of prior MI

1

88.4

86.7

86.1

84.2

86.4

86.1

88.7

90.0

83.0

86.9

2

10.1

12.4

12.6

13.6

12.2

11.3

10.4

8.5

14.7

11.2

≥ 3

1.5

0.9

1.3

2.2

1.5

2.6

0.9

1.5

2.4

1.8

History of diabetes

13.4

8.1

9.2

8.8

9.9

17

10.4

7.8

10.1

11.3

History of renal impairment

4.2

4.6

5.2

6.6

5.2

3.7

4.3

4.9

6.8

4.9

Gout flaresd

3.1

4.4

4.3

8.3

5.0

3.5

2.2

4.5

7.3

4.4

Medications, %

Gout medicationsd, e

4.2

4.1

3.1

5.0

4.1

3.3

2.0

4.5

4.8

3.7

Non-aspirin NSAIDs

1.5

1.7

0.4

1.8

1.3

0.7

0.9

0.9

1.3

1.0

Anti-diabetic medications

7.9

2.8

3.5

3.3

4.4

8.0

4.8

3.4

5.7

5.5

Blood pressure medications

5.7

8.3

8.9

18.4

10.3

6.4

7.8

8.5

16.7

9.8

Lipid-lowering medications

5.3

5.7

4.6

4.6

5.1

4.9

3.9

5.4

3.8

4.5

Follow-up time, years (SD)f

2.9

(0.5)

2.9

(0.5)

2.8

(0.5)

2.8

(0.5)

2.8

(0.5)

2.8

(0.5)

2.8

(0.5)

2.9

(0.5)

2.8

(0.6)

2.8

(0.5)

Minimum (years)

1.0

0.9

0.9

0.9

0.9

0.90

0.90

0.8

0.9

0.8

Maximum (years)

3.2

3.2

3.2

3.2

3.2

3.2

3.2

3.2

3.1

3.2


a < 1.5 oz/day; bIncludes cigarettes, pipes, and cigars; c > 45 cigarettes/day; dGout flares and medications determined at baseline; eIncludes probenecid, allopurinol, and colchicine; fFollow up from baseline to last observation. Mean (standard deviation) is provided unless specified otherwise. AMIS, Aspirin Myocardial infarction study; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; sUA, serum urate; SD, standard deviation.

Krishnan et al. Arthritis Research & Therapy 2012 14:R10   doi:10.1186/ar3684

Open Data